Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Trial ID or NCT#
NCT02320669
Status
RECRUITING
Purpose
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.
Official Title
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Eligibility Criteria
Ages Eligible for Study: Younger than 5 Months
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- 1. Informed consent obtained 2. Male and female patients <5 months (152 days) of age 3. Patients undergoing cardiopulmonary bypass
Exclusion Criteria:
- 1. Known thyroid disease (Down Syndrome is not an exclusion criterion unless patient has thyroid disease) 2. Trisomy 13 and 18 3. Prolonged preoperative ventilator support which would not be impacted by cardiac surgery (Lung disease: bronchopulmonary dysplasia, hypoplastic lungs associated with diaphragmatic hernia) 4. Any other condition as determined by the PI causing prolonged ventilator support which is unlikely to respond favorably to cardiac surgery 5. Prior participation in the clinical trial
Investigator(s)
Richard D. Mainwaring
View on ClinicalTrials.gov
